103 related articles for article (PubMed ID: 27185013)
1. Synthesis and evaluation of raloxifene derivatives as a selective estrogen receptor down-regulator.
Shoda T; Kato M; Fujisato T; Misawa T; Demizu Y; Inoue H; Naito M; Kurihara M
Bioorg Med Chem; 2016 Jul; 24(13):2914-2919. PubMed ID: 27185013
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and evaluation of tamoxifen derivatives with a long alkyl side chain as selective estrogen receptor down-regulators.
Shoda T; Kato M; Harada R; Fujisato T; Okuhira K; Demizu Y; Inoue H; Naito M; Kurihara M
Bioorg Med Chem; 2015 Jul; 23(13):3091-6. PubMed ID: 26003343
[TBL] [Abstract][Full Text] [Related]
3. Tamoxifen and Fulvestrant Hybrids Showed Potency as Selective Estrogen Receptor Down-Regulators.
Shoda T; Kato M; Fujisato T; Demizu Y; Inoue H; Naito M; Kurihara M
Med Chem; 2017; 13(3):206-213. PubMed ID: 27494098
[TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of tamoxifen derivatives as a selective estrogen receptor down-regulator.
Shoda T; Okuhira K; Kato M; Demizu Y; Inoue H; Naito M; Kurihara M
Bioorg Med Chem Lett; 2014 Jan; 24(1):87-9. PubMed ID: 24332630
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of marine sesterterpene analogues as novel estrogen receptor α degraders for breast cancer treatment.
Liang JJ; Yu WL; Yang L; Xie BH; Qin KM; Yin YP; Yan JJ; Gong S; Liu TY; Zhou HB; Hong K
Eur J Med Chem; 2022 Feb; 229():114081. PubMed ID: 34992039
[TBL] [Abstract][Full Text] [Related]
6. A new class of 1,3,5-triazine-based selective estrogen receptor degraders (SERDs): Lead optimization, molecular docking and dynamic simulation.
Lu X; Huang A; Xiao M; Sun L; Mao J; Luo G; Xiang H
Bioorg Chem; 2020 Apr; 97():103666. PubMed ID: 32088420
[TBL] [Abstract][Full Text] [Related]
7. Biological activities of a novel selective oestrogen receptor modulator derived from raloxifene (Y134).
Ning M; Zhou C; Weng J; Zhang S; Chen D; Yang C; Wang H; Ren J; Zhou L; Jin C; Wang MW
Br J Pharmacol; 2007 Jan; 150(1):19-28. PubMed ID: 17115070
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, biological evaluation, and stability studies of raloxifene mono- and bis-sulfamates as dual-targeting agents.
Zaraei SO; Dohle W; Anbar HS; El-Gamal R; Leblond B; Foster PA; Al-Tel TH; Potter BVL; El-Gamal MI
Bioorg Med Chem; 2024 Mar; 101():117645. PubMed ID: 38401456
[TBL] [Abstract][Full Text] [Related]
9. Novel class of 7-Oxabicyclo[2.2.1]heptene sulfonamides with long alkyl chains displaying improved estrogen receptor α degradation activity.
Hu Z; Li Y; Xie B; Ning W; Xiao Y; Huang Y; Zhao C; Huang J; Dong C; Zhou HB
Eur J Med Chem; 2019 Nov; 182():111605. PubMed ID: 31437778
[TBL] [Abstract][Full Text] [Related]
10. 1alpha,25-Dihydroxyvitamin D3 down-regulates estrogen receptor abundance and suppresses estrogen actions in MCF-7 human breast cancer cells.
Swami S; Krishnan AV; Feldman D
Clin Cancer Res; 2000 Aug; 6(8):3371-9. PubMed ID: 10955825
[TBL] [Abstract][Full Text] [Related]
11. Exploring the PROTAC degron candidates: OBHSA with different side chains as novel selective estrogen receptor degraders (SERDs).
Li Y; Zhang S; Zhang J; Hu Z; Xiao Y; Huang J; Dong C; Huang S; Zhou HB
Eur J Med Chem; 2019 Jun; 172():48-61. PubMed ID: 30939353
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and biological evaluation of new raloxifene analogues of improved antagonist activity and endometrial safety.
Lambrinidis G; Gouedard C; Stasinopoulou S; Angelopoulou A; Ganou V; Meligova AK; Mitsiou DJ; Marakos P; Pouli N; Mikros E; Alexis MN
Bioorg Chem; 2021 Jan; 106():104482. PubMed ID: 33272706
[TBL] [Abstract][Full Text] [Related]
13. Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
Baumann CK; Castiglione-Gertsch M
Minerva Ginecol; 2009 Dec; 61(6):517-39. PubMed ID: 19942839
[TBL] [Abstract][Full Text] [Related]
14. Dynamics-Based Discovery of Novel, Potent Benzoic Acid Derivatives as Orally Bioavailable Selective Estrogen Receptor Degraders for ERα+ Breast Cancer.
Zhang X; Wang Y; Li X; Wu J; Zhao L; Li W; Liu J
J Med Chem; 2021 Jun; 64(11):7575-7595. PubMed ID: 34056898
[TBL] [Abstract][Full Text] [Related]
15. Bis-arylidene oxindoles as anti-breast-cancer agents acting via the estrogen receptor.
Pal A; Ganguly A; Ghosh A; Yousuf M; Rathore B; Banerjee R; Adhikari S
ChemMedChem; 2014 Apr; 9(4):727-32. PubMed ID: 24482362
[TBL] [Abstract][Full Text] [Related]
16. Structure-activity relationship study of estrogen receptor down-regulators with a diphenylmethane skeleton.
Nanjyo S; Ohgane K; Yoshioka H; Makishima M; Hashimoto Y; Noguchi-Yachide T
Bioorg Med Chem; 2019 May; 27(10):1952-1961. PubMed ID: 30940565
[TBL] [Abstract][Full Text] [Related]
17. Discovery of novel 2H-chromene-3-carbonyl derivatives as selective estrogen receptor degraders (SERDs): Design, synthesis and biological evaluation.
Lu X; Teng Y; Lin X; Xiao M; Liu C; Chi X; Zhang Y; Luo G; Xiang H
Bioorg Chem; 2021 Apr; 109():104714. PubMed ID: 33618254
[TBL] [Abstract][Full Text] [Related]
18. A Screening Assay Cascade to Identify and Characterize Novel Selective Estrogen Receptor Downregulators (SERDs).
Callis R; Rabow A; Tonge M; Bradbury R; Challinor M; Roberts K; Jones K; Walker G
J Biomol Screen; 2015 Jul; 20(6):748-59. PubMed ID: 25851036
[TBL] [Abstract][Full Text] [Related]
19. The inhibitory effect of raloxifene on lipopolysaccharide-induced nitric oxide production in RAW264.7 cells is mediated through a ROS/p38 MAPK/CREB pathway to the up-regulation of heme oxygenase-1 independent of estrogen receptor.
Lee SA; Kim EY; Jeon WK; Woo CH; Choe J; Han S; Kim BC
Biochimie; 2011 Feb; 93(2):168-74. PubMed ID: 20888885
[TBL] [Abstract][Full Text] [Related]
20. Sulindac sulfide and exisulind inhibit expression of the estrogen and progesterone receptors in human breast cancer cells.
Lim JT; Joe AK; Suzui M; Shimizu M; Masuda M; Weinstein IB
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3478-84. PubMed ID: 16740773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
